Object. The authors evaluated the effects of acetylsalicylic acid (ASA) usage and transfusion of previously frozen apheresis platelets on postoperative hemorrhage, activities of daily living (ADL) score, and mortality rate in patients with acute hypertensive basal ganglia hemorrhage undergoing craniotomy.
A cetylsAlicylic acid (aspirin) is a widely used drug that can inhibit the aggregation of platelets. When used for the secondary prevention of cardiocerebrovascular disease, treatment with ASA yields a greater absolute reduction in serious vascular events, with a nonsignificant increase in hemorrhagic stroke but reductions of about one-fifth in the total number of strokes and coronary events. 1 Unfortunately, in patients with acute hypertensive basal ganglia hemorrhage after craniotomy for hematoma removal, ASA may increase the possibility of postoperative hemorrhage, as well as the disability rate and the mortality rate. The transfusion of both fresh and previously frozen apheresis platelets may decrease the possibility of postoperative hemorrhage, as well as lower the disability and mortality rates, and it has been proven that there is no significant difference between the effects of the two preparations. 17 However, the size of the therapeutic doses of platelets used in the study described were large and the indications were not clear. There are also patients who are resistant or only semiresponsive to ASA.
To examine the effects of ASA on postoperative hemorrhage following craniotomy and the usefulness of transfusion of apheresis platelets, we performed a prospective study. The study included 780 patients with acute hyperEffect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage tensive basal ganglia hemorrhage hospitalized from January 2004 to February 2011, all of whom underwent emergency craniotomy for hematoma removal. In the study, we examined the indications for the application and suitable therapeutic doses of previously frozen apheresis platelets in the prevention of postoperative hemorrhage in patients with acute hypertensive basal ganglia hemorrhage who had received ASA therapy prior to surgery.
Methods

Study Participants and Location
The study included patients with acute hypertensive basal ganglia hemorrhage who required emergency craniotomy for hematoma removal. The study protocol was approved by the Academic Committee and Ethics Committee of the Harrison International Peace Hospital. Written informed consent was obtained from all patients or their family members. Eligible participants were recruited between January 2004 and February 2011. Participants attended clinic visits or were followed up at the time of randomization (baseline) and at 2-month intervals for 6 months. The trial ended when we reached our sample size goal of 366 ASA-sensitive patients.
The inclusion criteria for the study were as follows:
1 diagnosis in line with the diagnostic criteria for hypertensive intracerebral hemorrhage revised by the Fourth National Cerebrovascular Disease Conference (China); 2, 5 diagnosis supported by CT/MRI, hemorrhagic brain regions in the basal ganglia area, and volumes of hemorrhage no less than 50 cm 3 ; 3 and stable vital signs. Patients with the following conditions were excluded from the study:
1 respiratory and circulatory failure; 2 medical history of nervous system diseases with neurological dysfunction sequelae; 3 severe heart, lung, liver, kidney and other major organ dysfunction; 4 recent history of surgery, trauma, or transfusion of blood or blood products; 5 cancer, hemorrhagic disease, or tendency to bleed; 6 significant mental retardation, psychoses, or other diseases affecting the patient's mental state; 7 recent use of drugs that affect blood coagulation; 8 abnormal platelet count; 9 pregnancy; 10 and membership in a transient population. The data were obtained in the Department of Neurosurgery, Harrison International Peace Hospital, which is attached to Hebei Medical University (third level, firstclass hospital) in Hengshui City, Hebei Province, People's Republic of China. Hengshui City is a major commercial city with a population of 4.11 million in its administrative area and an estimated 2000 patients with intracerebral hemorrhage every year.
Trial Design
The study was a prospective, single-center, doubleblind, parallel-group-designed, and randomized controlled trial. The patients in the study were divided into 5 groups. The control group, Group A, included patients with acute hypertensive basal ganglia hemorrhage who had never received ASA treatment before. The researchers who enrolled and assessed participants determined, according to the community doctor's records and the patient's knowledge of his/her own medical history, if a patient had received ASA.
For the patients who had received ASA therapy before, a platelet aggregation test was carried out by photoelectric turbidimetry immediately after the patient checked into the hospital. According to the criteria of Gum et al., 7 resistance to ASA was defined as a mean aggregation of greater than or equal to 70% with 10 mM adenosine diphosphate and a mean aggregation of greater than or equal to 20% with 0.5 mg/cm 3 arachidonic acid. Patients who met one but not both of the above criteria were defined as ASA semiresponders. Sensitivity to ASA was defined as meeting neither of the criteria.
7 Both ASAresistant and ASA-semiresponsive patients were assigned to Group B, and the ASA-sensitive patients were randomly assigned to 3 equally sized groups: Groups C, D, and E.
Sample Size, Patient Randomization, and Blinding
The following formula was used to determine the total sample size: n = (t 2 PQ)/d 2 , where n = sample size; P = rate of postoperative hemorrhage in all patients with acute hypertensive basal ganglia hemorrhage; Q = 1-P; d = admissible error; and t = 1.96, equivalent to the error of the first kind in t-distribution when degree of freedom approaches infinity for a value of 1-sided test. With an admissible error of 20%, n equals 100(Q/P). According to prior research, because the rate of postoperative hemorrhage in patients with acute hypertensive basal ganglia hemorrhage is 13.113% (107 of 816 patients), 17 n equals 663 for this study. Given an anticipated dropout rate of 10%-20%, a total sample size of approximately 800 patients was necessary. Recruitment of this number of patients required a 7-year study period. Prior research also indicated that 60.049% (490 of 816) of patients with acute hypertensive basal ganglia hemorrhage will have been treated with ASA, 17 so approximately 480 patients receiving ASA were required to enroll in the study. It has also been reported that the average incidence of ASA resistance and ASA semiresponsiveness is 24% (95% CI 20%-28%); 8 thus, approximately 115 ASA-resistant and ASA-semiresponsive patients were required to enroll in the study. The number of ASA-sensitive patients needed was 366.
The patients enrolled in the study were numbered according to their admission order. To randomize the 366 ASA-sensitive patients into 3 groups, their numbers were entered into the SPSS statistical package by an investigator with no clinical involvement in the trial, and a randomization sequence was created. The patients were then randomly assigned to 3 parallel groups. The allocation sequence was concealed from the researcher enrolling and assessing participants in sequentially numbered, opaque, sealed, and stapled envelopes. According to admission order number, the corresponding envelopes were opened only after the enrolled participants completed all baseline assessments and it was time to allocate the intervention. Participants and their family members and physicians allocated to the intervention group were aware of the allocated arm, but those assessing the outcomes of the trial, such as radiologists, outpatient/community doctors, and data analysts, were kept blind to the allocation.
Surgical Intervention
Following hospital admission, all drugs being used were withdrawn from the patients and they received immediate emergency craniotomy for removal of their hematoma. A senior anesthesiologist induced anesthesia, and the operation was performed in all cases by the same team and the same primary neurosurgeon. The craniotomy was performed through a small bone window. Under an operative microscope, the surgeon opened the sylvian fissure and exposed the insula, incised the cortex between the limen of the insula and the short gyrus of the insula, removed the intracerebral hematoma completely, and stopped all bleeding under direct vision. Finally, a drainage tube was placed in the residual cavity.
Postoperative therapy included pharmacotherapy such as dehydrating agents, neurotrophic agents, and antibiotics if necessary, as well as control of body temperature, water and electrolyte balance regulation, and hyperbaric oxygen therapy. Systolic blood pressure was strictly maintained below 160 mm Hg, 11 and proper sedative drugs were used to relieve restlessness and lessen the stimuli caused by removing the tracheal catheter and aspirating sputum. In conscious patients, emotion was kept stable, bowel movements were maintained, and so on. These measures were taken to exclude the influence of confounding factors in the trial.
In patients in whom the volume of postoperative hemorrhage exceeded 50 cm 3 , a second craniotomy for hematoma evacuation was performed, whereas the remaining patients were treated by infusing urokinase into the hematoma residual cavity from the drainage tube to dissolve and remove the blood clots.
Diagnostic Criteria for Postoperative Hemorrhage
A head CT scan was acquired immediately after the operation (in other words, after closing and dressing the surgical incision) to ensure that the hematoma was thoroughly cleared. If an accumulation of blood remained in the residual cavity, we considered it to have been caused by nonthorough hemostasis during the operation, but not by ASA. Cases in which this occurred were excluded from the trial, and the influence of nonthorough hemostasis during the operation was excluded. Additional head CT scan studies were performed at 24 and 48 hours after the operation and whenever the condition of patients changed. If any high-density image was observed in the hematoma residual cavity (a sign of rebleeding), regardless of the volume of the hemorrhage, a definite diagnosis of postoperative hemorrhage was made by professional radiologists who were kept blind to the allocation of the patient.
Transfusion of Platelets
The therapeutic measures given to patients in Groups A, B, and E were as mentioned above, namely conventional therapy without platelets. Patients in Groups A and E served as control groups for either not receiving ASA or receiving ASA with no additional treatment.
For Group C, in addition to the standard therapy given to Groups A, B, and E, previously frozen apheresis platelets were infused immediately after the patient was admitted to the hospital as the preoperative preparation was being carried out. One therapeutic dose of the apheresis platelets contained about 2.5 × 10 11 platelets. After fast thawing and rewarming, one therapeutic dose was infused at the fastest speed that patients could tolerate, and thus it could be infused completely in all patients before craniotomy for hematoma removal. Another therapeutic dose was infused after 24 hours of hospitalization. In other words, each patient received 2 therapeutic doses of previously frozen apheresis platelets within 48 hours of hospitalization.
The therapeutic methods used in Group D were almost the same as with Group C, but only one therapeutic dose of previously frozen apheresis platelets was infused before the operation and no infusion was given after the operation.
Measures and Outcomes
The outcome measures assessed in patients were postoperative hemorrhage rate and volume, ADL scores, and mortality rate. Postoperative hemorrhage volumes were measured using a computerized planimetric method and a simplified formula (Coniglobus formula) for the volume of an ellipsoid: ABC/2. 12 The derivation was as follows: The volume of an ellipsoid was (4/3)p(A/2)(B/2) (C/2), where A, B, and C were the three diameters, maximum width (A), length (B), and height (C). If p was estimated to be 3, then the volume of an ellipsoid became ABC/2.
For the ADL scores, in each group the patients were divided into different grades according to their ADL score 6 months postoperatively: Grade I, score of 100 (completely independent); Grade II, score of 75-95 (mildly dependent); Grade III, score of 50-70 (moderately dependent); Grade IV, score of 25-45 (severely dependent); and Grade V, score of 0-20 (completely dependent). 4 The predicted primary outcome was that the postoperative hemorrhage rate and the average postoperative hemorrhage volume of the patients who received the platelets (Groups C and D) would be similar to the level of Group A and would be different (significantly decreased) from the level of Group E. We expected that the results in Group B would be in line with those of Group A. The predicted secondary outcome was that the mortality rate of Groups C and D would be similar to the level of Group A and would be different (significantly decreased) from the level of Group E, and that the ADL scores obtained six months later in Groups C and D would be similar to the level of Group A and would be different (significantly increased) from the level of Group E. We expected that the results in Group B would be in line with those of Group A. Thus, we could avoid unnecessary waste of the platelets and achieve the objective of shortening the dosage through a comparison of Groups C and D.
Statistical Analysis
Statistical analysis and comparisons were performed using the SPSS 17.0 statistical package (IBM). The num-ber of postoperative hemorrhage cases, volume of postoperative hemorrhage, number of deaths, ADL scores, and the number of cases in the different ADL grades in the 5 groups were analyzed and compared through ANOVA, the least-significant difference t-test, the chi-square test, and the rank-sum test (Kruskal-Wallis test). Multiple pairwise comparisons increase the chance of a Type I error, namely an increase in the rate of false-positive results. Thus, the level of the tests was adjusted such that aʹ = a/the number of comparisons, and as there were 10 pairwise comparisons in the trial, so p < 0.005 indicated statistical significance and p < 0.001 indicated a highly significant difference. Mean results are presented ± SD.
Results
Study Participants
The flow of patients through the study is shown in Fig. 1 . A total of 1016 patients were screened, 196 of whom were deemed ineligible and 24 of whom met the inclusion criteria but declined to be enrolled. Of the 796 patients who were eligible and consented to enter the trial, 16 and member of a transient population, 7 cases. Among the study participants, 279 patients had not received ASA therapy before the occurrence of their intracerebral hemorrhage and formed Group A (control group), while the remaining 501 patients had taken ASA. In Group B (ASA-resistant/semiresponsive patients) there were 135 cases, accounting for 26.946% (135 of 501) of the total participants who had taken ASA. There were 122 cases in each of Groups C, D, and E. During the study we excluded 58 cases in total from the 5 groups because of incomplete hemostasis during the operation: 21 of 279 from Group A, 11 of 135 from Group B, 8 of 122 from Group C, 10 of 122 from Group D, and 8 of 122 from Group E. The total number of patients who completed the trial as per the protocol was 722 of the initial 780: 258 of 279 of those in Group A, 124 of 135 in Group B, 114 of 122 in Group C, 112 of 122 in Group D, and 114 of 122 in Group E. We followed all surviving patients for 6 months as planned, and there were no further lost cases.
The baseline data for each group are shown in Table 1, including demographic and clinical characteristics such as the Glasgow Coma Scale scores, 13 sex, age, hemorrhage volume, absence or presence of damage to the cerebral ventricle, blood pressure grade, 15 length of hypertensive history, and presence or absence of diabetes (blood pressure grade; see Table 7 )
Per-Protocol Analysis
The total number of cases of postoperative hemorrhage was 123 of 722 (17.036%), which all occurred within 3 days of the operation. ). There were significant differences among the 5 groups in the postoperative hemorrhage rate, average volume of postoperative hemorrhage, mortality rate, ADL scores, and the number of cases in all ADL grades (chi-square test 31.617, F = 10.759, chi-square test 25.620, F = 5.948, H = 20.213, respectively; all p = 0.000) ( Table 3) .
Intention-to-Treat Analysis
With the exception of the cases in which bleeding was caused by incomplete hemostasis during the operation, the cases of bleeding were all regarded as postoperative hemorrhage. There were 21 of 279 cases of bleeding that were caused by incomplete hemostasis in Group A; 16 of these patients survived and 5 died. In Group B, there were 11 of 135 cases that were caused by incomplete hemostasis; 8 of these patients survived and 3 died. In Group C, there were 8 of 122 cases caused by incomplete hemostasis; 6 of these patients survived and 2 died. In Group D, there were 10 of 122 cases of incomplete hemostasis; 8 of these patients survived and 2 died. Finally, in Group E, there were 8 of 122 cases of incomplete hemostasis; 5 of these patients survived and 3 died.
The total number of postoperative hemorrhage cases was 181 (23.205%) of 780, which all occurred within 3 days of the operation. In Group A there were 54 postoperative hemorrhages (19 Table 5) .
Outcomes
The primary outcome of the study was that the postoperative hemorrhage rate and the average postoperative hemorrhage volume in Groups C and D (with patients receiving platelets) were similar to the those in Group A (ASA naïve), namely a reduction of around 20% and 25 cm 3 , respectively, compared with Group E (ASA sensitive with no platelet transfusion). The secondary outcome of the study was that the mortality rate in Groups C and D was similar to that observed in Group A, namely a reduction of around 20% compared with Group E. Also, the ADL scores obtained 6 months after the operation were similar to those observed in Group A and were about 15 points higher than those in Group E. Each measure in Groups B, C, and D was basically consistent with those of Group A. We had achieved the objective of reducing the dosage of the previously frozen apheresis platelets. Table 6 provides an overview of patient groupings.
Participant Grouping Overview
Adverse Effects of Platelet Transfusion
No serious adverse events, such as anaphylactic shock, were recorded. All the participants were tested for the hepatitis viruses, HIV, and Treponema pallidum before platelet transfusion and when discharged from the hospital. The results were all negative. No patients were observed to be infected by blood transfusion-related infectious disease such as viral hepatitis, AIDS, syphilis, and so on.
Discussion
The main complication of hypertension is coronary heart disease in Western countries, while in China it is stroke. The incidence of stroke is five times greater than coronary heart disease. 9, 16 Therefore, stroke is a major disease that threatens Chinese people and treatments need to be developed to lessen the effects of the disease.
The transfusion of platelets is one method of preventing bleeding in patients with dysfunctional platelets. The main dosage forms of platelets that can be used include fresh apheresis platelets and previously frozen apheresis platelets. Fresh apheresis platelets can only be kept for a short time, but apheresis platelets frozen for later use in the clinic have many advantages such as the ability to keep a large stock, a much longer shelf life, increased safety, superior hemostasis effects, and the capacity to meet massive emergency clinical demand. It has also been proven that the transfusion of cryopreserved platelets has a remarkable effect on hemostasis and can enhance the platelet count in peripheral blood. 10 There is no statistical difference between the activity of previously frozen apheresis platelets and that of platelets stored at room temperature.
14 Additionally, after the platelets are frozen, the cryopreserved platelets were composed of distinct subpopulations of glycoprotein Ib-normal and glycoprotein Ib-reduced platelets. The glycoprotein Ibreduced subpopulation could increase binding of factor V and expression of P-selectin, both of which could promote the rapid hemostatic effect. 2 Therefore, we chose to use frozen apheresis platelets in this trial. As platelets are blood products, to avoid unnecessary waste and minimize blood transfusion-associated complications, the indications for platelet transfusions should be strictly followed and the minimum and proper doses used.
Acetylsalicylic acid is a COX inhibitor and inhibits platelet aggregation by irreversibly inhibiting COX-1 by acetylation of serine-529. 6 It is always the cornerstone drug in the secondary prevention of cardiocerebrovascular disease. 18 After taking ASA orally, the inhibitory action on COX can last 24 hours. In the normal state, platelets in circulation regenerate themselves by approximately 10% every day, and these new platelets are not affected by ASA taken 1 day before; they also have normal bloodclotting function. Studies have shown that in the normal state, only about 20% of platelets need to be unaffected by ASA to maintain the normal blood-clotting process. Regardless of issues such as a state of bodily stress following surgery, we suppose that the patients in Group C would be in a conventional state. In Group C, each patient was transfused with 2 therapeutic doses of previously frozen apheresis platelets within 48 hours of hospitalization (1 dose before surgery and 1 at 24 hours after hospitalization). As ASA administration was stopped upon hospitalization, after 48 hours 20% of the circulating platelets in the patient's body should have been regenerated and the risk of relapse hemorrhaging due to platelet dysfunction caused by ASA should have been mitigated completely. Therefore, continuation of platelet transfusion was not needed.
A cardiocerebrovascular accident is a common stressor, 3 and after an intracerebral hemorrhage, especially a large intracerebral hemorrhage, organisms enter a highstress state. Under this stress state, platelets are updated 19 which increases the proportion of platelets not inhibited by ASA in the circulating blood. Therefore, the platelets in circulation regenerate themselves by more than 10% per day in patients with massive intracerebral hemorrhage. We supposed that after 24 hours of hospitalization and cessation of ASA treatment, the risk of a relapse hemorrhage due to platelet dysfunction caused by ASA would have been reduced significantly and the patient might maintain an almost normal blood-clotting process. Therefore, in Group D, we only transfused 1 therapeutic dose of previously frozen apheresis platelets before surgery and did not administer platelets after surgery. Compared with Group C, this decreased the amount of platelets used by 50% with the same outcomes.
We conducted the study based on the information and perspectives outlined above. Our results show that almost all the measures in the different groups were the same between the per-protocol analysis and the intention-to-treat analysis. However, in terms of the postoperative hemorrhage rate, the difference between Groups B and E was significant at the level of p < 0.005, as was the difference between Groups D and E in terms of the ADL scores and the number of cases at all grades in the intention-to-treat analysis. In the per-protocol analysis these differences were significant at the p < 0.001 level (Tables 3 and 5) .
Principal Findings
The principal findings of the study were as follows. 1) For patients in Group E (ASA sensitive, no platelet transfusion), the postoperative hemorrhage rate, average volume of postoperative hemorrhage, and mortality rate were significantly higher than those in Group A (ASA naïve). Similarly, the ADL scores obtained 6 months postoperatively and the number of cases in each of the ADL grades for Group E were lower than those of Group A (all p = 0.000). The results indicate that ASA treatment can increase the chance of postoperative hemorrhage, the disability rate, and mortality rate in patients with acute hypertensive basal ganglia hemorrhage.
2) The patients in Group B were either resistant or semiresponsive to ASA and the average volume of their postoperative hemorrhage, postoperative hemorrhage rate, and mortality rate were lower than those in Group E. The ADL scores and number of cases in all ADL grades in Group B were also higher than those in Group E, and all the data were significantly different. In contrast, no significant differences were found between Groups A and B, indicating that in ASA-resistant or semiresponsive patients the use of ASA does not increase the possibility of postoperative hemorrhage, and thus it is unnecessary to give them platelets transfusions.
3) Groups C and D contained patients who were sensitive to ASA. We transfused 2 therapeutic doses of previously frozen apheresis platelets into patients in Group C and 1 therapeutic dose into patients in Group D. The average volume of postoperative hemorrhage, postoperative hemorrhage rate, and mortality rate in Groups C and D were all lower than those in Group E. The ADL scores and the number of cases in each ADL grade were higher than those of Group E. All the data were significantly different between Group E and Groups C and D, but those between C and D were not significantly different from each other or from Group A. These results indicate that the use of previously frozen apheresis platelets can reduce the possibility of postoperative hemorrhage, the disability rate, and the mortality rate in patients with acute hypertensive basal ganglia hemorrhage. A single therapeutic dose of previously frozen apheresis platelets before surgery could effectively prevent the increased likelihood of postoperative hemorrhage caused by ASA in ASA-sensitive patients. 4) When comparing Groups A and C, Groups A and D, Groups B and C, and Groups B and D, there were no significant differences in all the measures assessed, which further demonstrates the aforementioned conclusions. The use of previously frozen apheresis platelets is an effective therapeutic method for treating patients with hypertensive basal ganglia hemorrhage who have received ASA treatment before their illness. The transfusion of platelets is also an effective method for treating patients with bleeding or a tendency toward bleeding caused by ASA. By extension, the same result may apply to fresh apheresis platelets. However, although the indication and dosage for the use of fresh apheresis platelets should be the same as with previously frozen apheresis platelets, further exploration is needed. 5) In Groups B and D, the average volume of postoperative hemorrhage and the mortality rates were slightly higher than those in Groups A and C. The ADL scores were also slightly lower in Groups B and D than in Groups A and C. Although these differences were not statistically significant, this finding may suggest the following: 1 i) ASA has a certain level of effect on platelet inhibition in ASA-resistant and ASA-semiresponsive patients;
2 ii) although the platelets regenerate faster in ASAsensitive patients with massive intracerebral hemorrhage, the newly generated platelets may be less than 20% of the total amount after 24 hours of hospitalization, and the risk of postoperative hemorrhage caused by ASA may not be completely diminished.
Trial Limitations
One limitation of the trial was that the patients in Groups A and B did not undergo random allocation, but the baseline data including the demographic and clinical characteristics of the 5 groups were well balanced and they were comparable. The patients in Group A served as a control group, which was approved by a statistician from Hebei Medical University. Another limitation of the trial was that multiple pairwise comparisons increase the 
Conclusions
The use of ASA cannot only increase the possibility of postoperative hemorrhage in patients with acute hypertensive basal ganglia hemorrhage, but also the disability and mortality rates. Transfusion of previously frozen apheresis platelets can reduce the chance of postoperative hemorrhage, as well as the disability and mortality rates. The indications for platelet use and dose are such that in patients who are resistant or semiresponsive to ASA the rates of postoperative hemorrhage, disability, and mortality are lowered and transfusion of platelets is not necessary. Furthermore, in ASA-sensitive patients only 1 transfusion of previously frozen apheresis platelets is required before craniotomy for hematoma removal, a transfusion that can effectively prevent the increased likelihood of postoperative hemorrhage caused by ASA and reduce the postoperative hemorrhage rate, the average postoperative hemorrhage volume, the disability rate, and the mortality rate in these patients. 
